Merck (MRK) Free Cash Flow (2009 - 2026)
Merck (MRK) reported Free Cash Flow of $2.9 billion for Q1 2026, up 149.74% year-over-year from $1.2 billion in Q1 2025, and up 60.47% on a QoQ basis from $1.8 billion in Q4 2025.
Merck (MRK) has 18 years of Free Cash Flow data on file, last reported at $2.9 billion in Q1 2026.
- Quarterly Free Cash Flow rose 149.74% year-over-year to $2.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.1 billion (down 17.16% YoY) and the FY2025 annual result came in at $12.4 billion, down 31.7% from the prior year.
- Free Cash Flow climbed to $2.9 billion in Q1 2026 per MRK's latest filing, from $1.8 billion in the prior quarter.
- Across five years, Free Cash Flow topped out at $8.5 billion in Q3 2024 and bottomed at -$743.0 million in Q4 2023.
- The 5-year median for Free Cash Flow is $2.9 billion (2026), against an average of $3.4 billion.
- The widest annual swing landed in 2022, when Free Cash Flow surged 2290.51%; it then plunged 122.65% in 2023.
- Tracing MRK's Free Cash Flow over 5 years: stood at $3.3 billion in 2022, then sank by 122.65% to -$743.0 million in 2023, then surged by 438.22% to $2.5 billion in 2024, then dropped by 27.42% to $1.8 billion in 2025, then soared by 60.47% to $2.9 billion in 2026.
- Per Business Quant, the three latest MRK Free Cash Flow figures stand at $2.9 billion (Q1 2026), $1.8 billion (Q4 2025), and $6.8 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 346.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 1.47 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 3.56 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 757.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.93 Bn |
| Mar 31, 2026 | 2.93 Bn |
| Dec 31, 2025 | 1.82 Bn |
| Dec 31, 2025 | 1.82 Bn |
| Sep 30, 2025 | 6.84 Bn |
| Sep 30, 2025 | 6.84 Bn |
| Jun 30, 2025 | 2.53 Bn |
| Jun 30, 2025 | 2.53 Bn |
| Mar 31, 2025 | 1.17 Bn |
| Mar 31, 2025 | 1.17 Bn |
| Dec 31, 2024 | 2.51 Bn |
| Dec 31, 2024 | 2.51 Bn |
| Sep 30, 2024 | 8.51 Bn |
| Sep 30, 2024 | 8.51 Bn |
| Jun 30, 2024 | 4.85 Bn |
| Jun 30, 2024 | 4.85 Bn |
| Mar 31, 2024 | 2.23 Bn |
| Mar 31, 2024 | 2.23 Bn |
| Dec 31, 2023 | -743.00 Mn |
| Dec 31, 2023 | -743.00 Mn |
| Sep 30, 2023 | 6.82 Bn |
| Sep 30, 2023 | 6.82 Bn |
| Jun 30, 2023 | 2.74 Bn |
| Jun 30, 2023 | 2.74 Bn |
| Mar 31, 2023 | 332.00 Mn |
| Mar 31, 2023 | 332.00 Mn |
| Dec 31, 2022 | 3.28 Bn |
| Dec 31, 2022 | 3.28 Bn |
| Sep 30, 2022 | 4.48 Bn |
| Sep 30, 2022 | 4.48 Bn |
| Jun 30, 2022 | 3.17 Bn |
| Jun 30, 2022 | 3.17 Bn |
| Mar 31, 2022 | 3.78 Bn |
| Mar 31, 2022 | 3.78 Bn |
| Dec 31, 2021 | 3.89 Bn |
| Dec 31, 2021 | 3.89 Bn |
| Sep 30, 2021 | 3.63 Bn |
| Sep 30, 2021 | 3.63 Bn |
| Jun 30, 2021 | 1.00 Bn |
| Jun 30, 2021 | 1.00 Bn |
| Mar 31, 2021 | 158.00 Mn |
| Mar 31, 2021 | 158.00 Mn |
| Dec 31, 2020 | 1.98 Bn |
| Dec 31, 2020 | 1.98 Bn |
| Sep 30, 2020 | 1.28 Bn |
| Sep 30, 2020 | 1.28 Bn |
| Jun 30, 2020 | 1.35 Bn |
| Jun 30, 2020 | 1.35 Bn |
| Mar 31, 2020 | -279.00 Mn |
| Mar 31, 2020 | -279.00 Mn |
| Dec 31, 2019 | -795.00 Mn |
| Dec 31, 2019 | -795.00 Mn |
| Sep 30, 2019 | 3.27 Bn |
| Sep 30, 2019 | 3.27 Bn |
| Jun 30, 2019 | 2.30 Bn |
| Jun 30, 2019 | 2.30 Bn |
| Mar 31, 2019 | 741.00 Mn |
| Mar 31, 2019 | 741.00 Mn |
| Dec 31, 2018 | 2.66 Bn |
| Dec 31, 2018 | 2.66 Bn |
| Sep 30, 2018 | 2.14 Bn |
| Sep 30, 2018 | 2.14 Bn |
| Jun 30, 2018 | 2.80 Bn |
| Jun 30, 2018 | 2.80 Bn |
| Mar 31, 2018 | 705.00 Mn |
| Mar 31, 2018 | 705.00 Mn |
| Dec 31, 2017 | 3.30 Bn |
| Dec 31, 2017 | 3.30 Bn |
| Sep 30, 2017 | -1.61 Bn |
| Sep 30, 2017 | -1.61 Bn |
| Jun 30, 2017 | 2.92 Bn |
| Jun 30, 2017 | 2.92 Bn |
| Mar 31, 2017 | -53.00 Mn |
| Mar 31, 2017 | -53.00 Mn |
| Dec 31, 2016 | 3.08 Bn |
| Dec 31, 2016 | 3.08 Bn |
| Sep 30, 2016 | 2.56 Bn |
| Sep 30, 2016 | 2.56 Bn |
| Jun 30, 2016 | 1.23 Bn |
| Jun 30, 2016 | 1.23 Bn |
| Mar 31, 2016 | 1.89 Bn |
| Mar 31, 2016 | 1.89 Bn |
| Dec 31, 2015 | 3.75 Bn |
| Dec 31, 2015 | 3.75 Bn |
| Sep 30, 2015 | 3.00 Bn |
| Sep 30, 2015 | 3.00 Bn |
| Jun 30, 2015 | 2.43 Bn |
| Jun 30, 2015 | 2.43 Bn |
| Mar 31, 2015 | 2.08 Bn |
| Mar 31, 2015 | 2.08 Bn |
| Dec 31, 2014 | -1.53 Bn |
| Dec 31, 2014 | -1.53 Bn |
| Sep 30, 2014 | 4.03 Bn |
| Sep 30, 2014 | 4.03 Bn |
| Jun 30, 2014 | 2.01 Bn |
| Jun 30, 2014 | 2.01 Bn |
| Mar 31, 2014 | 2.16 Bn |
| Mar 31, 2014 | 2.16 Bn |
| Dec 31, 2013 | 2.60 Bn |
| Dec 31, 2013 | 2.60 Bn |
| Sep 30, 2013 | 3.59 Bn |
| Sep 30, 2013 | 3.59 Bn |
| Jun 30, 2013 | 1.93 Bn |
| Jun 30, 2013 | 1.93 Bn |
| Mar 31, 2013 | 1.99 Bn |
| Mar 31, 2013 | 1.99 Bn |
| Dec 31, 2012 | 1.03 Bn |
| Dec 31, 2012 | 1.03 Bn |
| Sep 30, 2012 | 2.73 Bn |
| Sep 30, 2012 | 2.73 Bn |
| Jun 30, 2012 | 2.49 Bn |
| Jun 30, 2012 | 2.49 Bn |
| Mar 31, 2012 | 1.82 Bn |
| Mar 31, 2012 | 1.82 Bn |
| Dec 31, 2011 | 2.63 Bn |
| Dec 31, 2011 | 2.63 Bn |
| Sep 30, 2011 | 4.15 Bn |
| Sep 30, 2011 | 4.15 Bn |
| Jun 30, 2011 | 2.49 Bn |
| Jun 30, 2011 | 2.49 Bn |
| Mar 31, 2011 | 1.40 Bn |
| Mar 31, 2011 | 1.40 Bn |
| Dec 31, 2010 | 2.88 Bn |
| Dec 31, 2010 | 2.88 Bn |
| Sep 30, 2010 | 2.25 Bn |
| Sep 30, 2010 | 2.25 Bn |
| Jun 30, 2010 | 2.99 Bn |
| Jun 30, 2010 | 2.99 Bn |
| Mar 31, 2010 | 1.02 Bn |
| Mar 31, 2010 | 1.02 Bn |
| Dec 31, 2009 | 1.69 Bn |
| Dec 31, 2009 | 1.69 Bn |
| Sep 30, 2009 | -615.40 Mn |
| Sep 30, 2009 | -615.40 Mn |
| Jun 30, 2009 | 383.80 Mn |
| Jun 30, 2009 | 383.80 Mn |
| Mar 31, 2009 | 477.50 Mn |
| Mar 31, 2009 | 477.50 Mn |